Renalytix plc (RNLXY) stock
Close on Oct 19, 2026Market cap $375.75MP/E –Yield –
Renalytix plc saw revenue fall 18.7% to $2.35M over the twelve months to Sep 30, 2024. At the latest close the market valued the company at $375.75M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2024
Valuation
- Market cap
- $375.75M
- P/E ratio
- –
- Price to sales
- 159.76
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.35M
- Net income
- -$28.03M
- EPS, diluted
- -$0.26
- Book value per share
- -$0.11
- Diluted shares
- 106M
Trading
- Previous close
- $3.50
- Open
- $3.58
- Day's range
- $3.56 – $3.58
- Volume
- 2,860
- Average volume (20 days)
- 4,937
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | RNLXY | S&P 500 | Difference | RNLXY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.3% | +0.6% | −15.0 pts | ||
| 3 months | +92.2% | +3.4% | +88.8 pts | ||
| Year to date | -1.8% | +13.3% | −15.1 pts | ||
| 1 year | -97.9% | +16.6% | −114.5 pts | ||
| 3 years | -99.6% | +86.4% | −185.9 pts | -83.7% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.8 pts | -81.2% | +12.7% |
Seven years at a glance
Fiscal years 2018 to 2024 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Renalytix filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Results
- Results
About Renalytix
Services-Medical Laboratories
Renalytix plc is an in vitro diagnostics company focused on managing kidney disease through artificial intelligence-enabled prognostic tools. The company develops and provides diagnostic services designed to assess the risk of progressive kidney function decline in adults with type 2 diabetes and early-stage chronic kidney disease. Its core offering, kidneyintelX.dkd, combines blood biomarkers with clinical algorithms to assist clinicians in identifying individuals who require early medical intervention before major organ damage occurs. The company markets its diagnostic testing services primarily to healthcare providers, primary care physicians, and clinical networks across the healthcare sector.
Company profile, executives and historyRenalytix stock: common questions
What is Renalytix's stock price?
RNLXY closed at $3.56 on Oct 19, 2026, up 1.57% on the day.
What is Renalytix's market cap?
Renalytix was worth $375.75M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is RNLXY's P/E ratio?
Renalytix lost money over the twelve months to Sep 30, 2024 (diluted EPS -$0.26), so it has no meaningful P/E ratio.
How much revenue does Renalytix make?
Renalytix reported revenue of $2.35M for the twelve months to Sep 30, 2024, down 18.7% from a year earlier.
Does Renalytix pay a dividend?
No. Renalytix has not paid a cash dividend over the last twelve months.
How has RNLXY stock performed over the past year?
Including dividends, RNLXY returned -97.9% over the past year, against +16.6% for the S&P 500.
Who are Renalytix's competitors?
Companies most similar to Renalytix by business, industry and size include SERA, XGN, CDNA, MDXH, BDSX.
See a number that looks wrong?